Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants

我们将创造一种合成微流控水凝胶的良性技术，以在骨植入物中产生人工血管培养。这是能够在终末期器官衰竭患者中使用组织工程重要器官，如骨、心脏和肾脏的关键一步。更厚的支架将成为可能，因为血管系统将为细胞生长为3D支架提供营养和氧气。它将促进澳大利亚制造用于组织工程的全球生物材料产品的能力。我们还将开发用于快速分析广泛的功能分子阵列的原位成像分析协议，这对生物微机械系统的设计具有重要意义，以开发诊断致命疾病的方法。

We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.